# Kevin Walton

> Kevin Walton is the Chief Executive Officer and Board Director of Baseimmune, a London-based biotech using AI and computational protein design to build next-generation vaccines and active immunotherapies. He joined in 2024 after a career in biotech corporate development and dealmaking at Moderna, StrideBio, Curis and G1 Therapeutics, and is steering the company beyond infectious-disease vaccines into chronic diseases, starting with a lead fibrosis program in idiopathic pulmonary fibrosis.

- **Role:** Chief Executive Officer & Board Director at Baseimmune
- **Organizations:** Baseimmune, Moderna, StrideBio, Curis, G1 Therapeutics, Torreya Partners, CRA International, Amgen, Eli Lilly and Company
- **Nationality:** American
- **Education:** Juris Doctor (J.D.), magna cum laude, Duke University School of Law, MBA (Fuqua Scholar), Duke University, Fuqua School of Business, B.A., Economics and History, Boston College
- **Known for:** Appointed CEO of Baseimmune in 2024 to lead its expansion into chronic diseases and multi-pathway biology, Directed Baseimmune's 2026 strategic move into fibrosis therapeutics, with a lead program targeting idiopathic pulmonary fibrosis, Built a career spanning corporate development, M&A and business development across Moderna, StrideBio, Curis and G1 Therapeutics

## Career timeline

- **Early career** — Finance and strategy roles at Amgen and Eli Lilly and Company; consulting at CRA International
- **—** — Analyst at Torreya Partners, advising on pharmaceutical M&A and licensing
- **—** — G1 Therapeutics: Senior Manager of Business Development, Chief of Staff, and Director of Corporate Development & Strategy
- **2021-2022** — Senior Director of Business Development at Curis
- **2022-2023** — Vice President of Corporate Development at StrideBio
- **2023** — Senior Director of Corporate Development at Moderna
- **2024** — Appointed Chief Executive Officer & Board Director of Baseimmune
- **2026** — Led Baseimmune's expansion into fibrosis with a lead program in idiopathic pulmonary fibrosis (IPF)

## Achievements

- Appointed CEO of Baseimmune in 2024 to lead its expansion into chronic diseases and multi-pathway biology
- Directed Baseimmune's 2026 strategic move into fibrosis therapeutics, with a lead program targeting idiopathic pulmonary fibrosis
- Built a career spanning corporate development, M&A and business development across Moderna, StrideBio, Curis and G1 Therapeutics
- Earned a J.D. magna cum laude from Duke Law and an MBA as a Fuqua Scholar

## Latest updates

- **2026-03** — Baseimmune announced its strategic expansion into fibrosis with a lead program targeting idiopathic pulmonary fibrosis (IPF), with proof-of-concept efficacy readouts expected in 2026 and 2027.

## Links

- Website: https://baseimmune.co.uk
- LinkedIn: http://www.linkedin.com/in/kjdwalton

---

Profile page: https://yespress.io/kevin-walton
Published by YesPress — https://yespress.io
Last updated: 2026-07-15